|
1
|
Grundt K, Haga IV, Aleporou-Marinou V,
Drosos Y, Wanvik B and Østvold AC: Characterization of the NUCKS
gene on human chromosome 1q32.1 and the presence of a homologous
gene in different species. Biochem Biophys Res Comm. 323:796–801.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ostvold AC, Norum JH, Mathiesen S, Wanvik
B, Sefland I and Grundt K: Molecular cloning of a mammalian nuclear
phosphoprotein NUCKS, which serves as a substrate for Cdk1 in vivo.
Eur J Biochem. 268:2430–2440. 2001. View Article : Google Scholar
|
|
3
|
Wiśniewski JR and Schwanbeck R: High
mobility group I/Y: multifunctional chromosomal proteins causally
involved in tumor progression and malignant transformation
(review). Int J Mol Med. 6:409–419. 2000.
|
|
4
|
Fusco A and Fedele M: Roles of HMGA
proteins in cancer. Nat Rev Cancer. 7:899–910. 2007. View Article : Google Scholar
|
|
5
|
Belge G, Meyer A, Klemke M, Burchardt K,
Stern C, Wosniok W, Loeschke S and Bullerdiek J: Upregulation of
HMGA2 in thyroid carcinomas: a novel molecular marker to
distinguish between benign and malignant follicular neoplasias.
Genes Chromosomes Cancer. 47:56–63. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Schaner ME, Ross DT, Ciaravino G, Sorlie
T, Troyanskaya O, Diehn M, Wang YC, Duran GE, Sikic TL, Caldeira S,
Skomedal H, Tu IP, Hernandez-Boussard T, Johnson SW, O’Dwyer PJ,
Fero MJ, Kristensen GB, Borresen-Dale AL, Hastie T, Tibshirani R,
van de Rijn M, Teng NN, Longacre TA, Botstein D, Brown PO and Sikic
BI: Gene expression patterns in ovarian carcinomas. Mol Biol Cell.
14:4376–4386. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kikuchi A, Ishikawa T, Mogushi K, Ishiguro
M, Iida S, Mizushima H, Uetake H, Tanaka H and Sugihara K:
Identification of NUCKS1 as a colorectal cancer prognostic marker
through integrated expression and copy number analysis. Int J
Cancer. 132:2295–2302. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Smalley M and Ashworth A: Stem cells and
breast cancer: a field in transit. Nat Cancer. 3:832–844. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Weigelt B, Geyer FC, Horlings HM, Kreike
B, Halfwerk H and Reis-Filho JS: Mucinous and neuroendocrine breast
carcinomas are transcriptionally distinct from invasive ductal
carcinomas of no special type. Mod Pathol. 22:1401–1414. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Goldhirsch A, Wood WC, Coates AS, Gelber
RD, Thürlimann B and Senn HJ; Panel members. Strategies for
subtypes - dealing with the diversity of breast cancer: highlights
of the St. Gallen international expert consensus on the primary
therapy of early breast cancer 2011. Ann Oncol. 22:1736–1747. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Carey LA, Perou CM, Livasy CA, Dressler
LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S,
Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS
and Millikan RC: Race, breast cancer subtypes and survival in the
Carolina Breast Cancer Study. JAMA. 295:2492–2502. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Perou CM, Sørlie T, Eisen MB, van de Rijn
M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA,
Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE,
Børresen-Dale AL, Brown PO and Botstein D: Molecular portraits of
human breast tumors. Nature. 406:747–752. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ziółkowski P, Gamian E, Osiecka B, Zougman
A and Wiśniewski JR: Immunohistochemical and proteomic evaluation
of nuclear ubiquitous casein and cyclin-dependent kinases substrate
in invasive ductal carcinoma of the breast. J Biomed Biotechnol.
2009:9196452009.PubMed/NCBI
|
|
14
|
Fernandes RC, Bevilacqua JL, Soares IC,
Siqueira SA, Pires L, Hegg R and Carvalho FM: Coordinated
expression of ER, PR and HER2 define different prognostic subtypes
among poorly differentiated breast carcinomas. Histopathology.
55:346–352. 2009. View Article : Google Scholar
|
|
15
|
Cheang MC, Chia SK, Voduc D, Gao D, Leung
S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM,
Ellis MJ and Nielsen TO: Ki-67 index, HER2 status and prognosis of
patients with luminal B breast cancer. J Natl Cancer Inst.
101:736–750. 2009. View Article : Google Scholar
|
|
16
|
Elston CW and Ellis IO: Pathological
prognostic factors in breast cancer. I The value of histological
grade in breast cancer: experience from a large study with
long-term follow-up. Histopathology. 19:403–410. 1991. View Article : Google Scholar
|
|
17
|
Allred DC, Harvey JM, Berardo M and Clark
GM: Prognostic and predictive factors in breast cancer by
immunohistochemical analysis. Mod Pathol. 111:155–168.
1998.PubMed/NCBI
|
|
18
|
McClave JT, Benson PG and Sincich T: A
First Course in Business Statistics. 17th edition. Prentice-Hall,
Inc; New York, NY: 1998
|
|
19
|
Hwang-Verslues WW, Kuo WH, Chang PH, Pan
CC, Wang HH, Tsai ST, Jeng YM, Shew JY, Kung JT, Chen CH, Lee EY,
Chang KJ and Lee WH: Multiple lineages of human breast cancer
stem/progenitor cells identified by profiling with stem cell
markers. PLoS One. 4:e83772009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Skaland I, Janssen EA, Gudlaugsson E, Hui
Ru Guo L and Baak JP: The prognostic value of the proliferation
marker phosphohistone H3 (PPH3) in luminal, basal-like and triple
negative phenotype invasive lymph node-negative breast cancer. Cell
Oncol. 31:261–271. 2009.
|
|
21
|
Grundt K, Skjeldal L, Anthonsen HW, Skauge
T, Huitfeldt HS and Østvold AC: A putative DNA-binding domain in
the NUCKS protein. Arch Biochem Biophys. 407:168–175. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wiśniewski JR, Zougman A, Krüger S,
Ziółkowski P, Pudełko M, Bebenek M and Mann M: Constitutive and
dynamic phosphorylation and acetylation sites on NUCKS, a
hypermodified nuclear protein, studied by quantitative proteomics.
Proteins. 73:710–718. 2008.PubMed/NCBI
|
|
23
|
Bernardi MA, Logullo AF, Pasini FS,
Nonogaki S, Blumke C, Soares FA and Brentani MM: Prognostic
significance of CD24 and claudin-7 immunoexpression in ductal
invasive breast cancer. Oncol Rep. 27:28–38. 2012.PubMed/NCBI
|
|
24
|
Yanagawa M, Ikemot K, Kawauchi S, Furuya
T, Yamamoto S, Oka M, Oga A, Nagashima Y and Sasaki K: Luminal A
and luminal B (HER2 negative) subtypes of breast cancer consist of
a mixture of tumors with different genotype. BMC Res Notes.
5:3762012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cheang MCU, Voduc D, Bajdik C, Leung S,
McKinney S, Chia SK, Perou CM and Nielsen TO: Basal-like breast
cancer defined by five biomarkers has superior prognostic value
than triple-negative phenotype. Clin Cancer Res. 14:1368–1376.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chu PG and Weiss LM: Expression of
cytokeratin 5/6 in epithelial neoplasms: an immunohistochemical
study of 509 cases. Mod Pathol. 15:6–10. 2012.
|
|
27
|
Khilko N, Wang J, Wei B, Hicks DG and Tang
P: Invasive lobular carcinomas do not express basal cytokeratin
markers CK 5/6, CK 14 and CK 17. Breast Cancer (Auckl). 21:49–55.
2010.PubMed/NCBI
|
|
28
|
Abd El-Rehim DM, Pinder SE, Paish CE, Bell
J, Blamey RW, Robertson JF, Nicholson RI and Ellis IO: Expression
of luminal and basal cytokeratins in human breast carcinoma. J
Pathol. 203:661–671. 2004.PubMed/NCBI
|
